Corvus Pharmaceuticals (CRVS) Hits All-Time High on Eczema Trial Results

We recently published 10 Stocks Delivering Double-Digit Gains Effortlessly; 4 Hit Highs. Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) was one of the best performers on Thursday.

Corvus Pharmaceuticals extended its winning streak to a 6^th straight session on Thursday to hit a new all-time high, as investors cheered strong results from the clinical trial testing the efficacy of soquelitinib in patients with moderate to severe eczema.

At intra-day trading, the stock soared to its highest price of $26.22 before paring gains to end the day just up by 15.21 percent at $25.52 apiece.

In an updated report, Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) said that soquelitinib successfully demonstrated a 72 percent reduction in the severity of enrolled patients’ eczema, as compared with the 40 percent for those who took the placebo.

Additionally, the drug candidate was observed to be even more effective when taken longer, and that it was well-tolerated.

Based on the positive results, Corvus Pharmaceuticals Inc. (NASDAQ:CRVS) said that it plans to initiate a Phase 2 trial in the first quarter of 2026 and enroll 200 patients with moderate-to-severe atopic dermatitis that have failed at least one prior topical or systemic therapy.

The trial is anticipated to enroll four cohorts of 50 patients each, with soquelitinib doses of: 200 mg once per day; 200 mg twice per day; and 400 mg once per day; along with a placebo group.

The Phase 2 trial is targeted to run for 12 weeks with a 30-day follow-up period without treatment.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.